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Abstract
Objective
The aim was to describe a broad range of health dimensions in possibly
benign multiple sclerosis (MS) hypothesizing that despite some limitations
there is a high adaptation to the disease.
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Methods
All patients from an outpatient university clinic data registry with an
Expanded Disability Status Scale (EDSS) ≤3.5 and disease duration ≥15 years
were addressed in a cross-sectional study. Physical impairment,
neuropsychological functioning but also influence on activities and patient
reported outcome measures including coping were studied.
Results
One hundred and twenty-five patients could be included (mean EDSS: 2.8;
mean disease duration: 24 years). Cognitive impairment was minor (8%) but
fatigue (73%) and depression (46%) were prevalent. Nevertheless, QOL and
daily activities seemed to be less affected. Patients showed high social
support, coping abilities, and sense of coherence, which was predictive for
their perceived benignity of the disease. Based on the EDSS alone, we
estimated the rate of benign MS after 15 years of MS as high as 23%
decreasing to 16% if cognition was included in the definition. However,
cognitive performance was not relevantly associated with other outcomes.
Conclusion
Common benign MS definitions seem to simplify a complex disease picture
where different impairments and personal resources lead to more or less
impact on people’s lives.
Graphical Abstract
The concept of benign multiple sclerosis (MS) is an important and heavily
discussed topic in research with direct impact on real-life clinical treatment
of patient with multiple sclerosis. In this cross-sectional study we described a
broad range of health dimensions in possibly benign multiple sclerosis
hypothesizing that despite of some limitations there is a high adaptation to
the disease. Besides physical impairments we focused on neuropsychological
abilities, sense of coherence, coping, and quality of life.
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1. INTRODUCTION
Multiple sclerosis (MS) is a chronic, unpredictable disease with a broad
variability in quality, severity, and evolution dynamics of symptoms
(Degenhardt, Ramagopalan, Scalfari, & Ebers, 2009). Lately, the term benign
multiple sclerosis (BMS) has been used to define patients with a milder disease
course characterized by low disability assessed by the Expanded Disability
Status Scale (EDSS) related to disease duration (Cristina, Vasconcelos, Maria,
& Alvarenga, 2017; Lublin & Reingold, 1996; Ramsaransing & De Keyser,
2006).
AQ4
Based on different cutoffs prevalence estimates differ substantially in the few
studies from 6%–74% (Cristina et al., 2017). The strongest approach here is to
reclaim no MS associated disability at all at life end classifying 5% of patients
as benign (Skoog, Runmarker, Winblad, Ekholm, & Andersen, 2012). Taking
also hidden MS symptoms as neuropsychiatric deficits into account the concept
of a benign variant has in addition been questioned (Amato et al., 2006;
Correale, Peirano, & Romano, 2012). Other studies claimed the predictive value
of this BMS definition (Costelloe, Thompson, Walsh, Tubridy, & Hutchinson,
2008; Leray et al., 2013; Sayao, Bueno, Devonshire, & Tremlett, 2011). In the
2014 revision of MS disease course definitions, a consensus group advised to
use the term BMS cautiously as even after years of a seemingly benign course
the disease may decompensate (Lublin et al., 2014). In recent years, few efforts
have been made to collect and describe putatively benign MS cohorts. However,
with higher sensitivity of diagnostic criteria and increasing number of licensed
treatments the open question is if all patients need to be treated as a benign
variant of the disease might not exist. Taking it differently: do neurologist have
the right to deny a possibly benign course of disease? The main aim of this
study was to describe a broad range of health dimensions in relation to a BMS
concept based on EDSS and disease duration. Special attention was payed to
neuropsychological impairment as well as to coping and daily functioning. We
hypothesized that despite of some limitations patients classified as BMS show a
high level of adaption to the disease.
2. MATERIALS AND METHODS
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2.1. Study design
MS patients fulfilling McDonald criteria (2005) were included in this cross-
sectional study who had presented at least once at the MS day hospital at the
university medical center Hamburg between January 1996 and June 2012 and
were considered having BMS based on a disease duration ≥15 years and an
EDSS score ≤3.5 at their last examination. Patients were recruited by letter and
gave their informed consent to the study. Patients were invited for an
assessment at the center and received questionnaires in advance. We aimed to
minimize a dropout bias as follows: In case patients were not able to take part in
the assessment a structured telephone interview was performed. Patients who
did not respond were contacted with a second letter including a feedback format
for gathering information about their nonresponsiveness and general clinical
status (stable, improved, worsen). The standardized assessment (July 2012–
January 2013) included neuropsychological and physical function as well as
nine questionnaires.
2.2. Clinical tests
Neurological impairment was assessed using the EDSS (Kurtzke, 1983). If
patients could not take part in the assessment EDSS was evaluated by phone
(Lechner-Scott et al., 2003). In patients only answering the feedback letter and
stating stability since their last examination we used their last EDSS. Mobility
and ambulation was tested with three tests. The 25-Foot Walk (T25FW)
(Stellmann, Vettorazzi, Poettgen, & Heesen, 2014) is one of the best evaluated
objective tests assessing gait impairment in a wide range in MS (Kempen et al.,
2011). In addition the 3-meter Timed Tandem Walk (TTW), (Stellmann et al.,
2014) and the 6-min Walking Test (6MWT)(Goldman, Marrie, & Cohen, 2008)
were assessed. These tests are more sensitive to detect disability especially in
mild affected patients and addresses additionally balance and fatigability
(Kieseier & Pozzilli, 2012; Stellmann et al., 2014). Furthermore, the nine hole
peg test (9HPT), for upper limb function was included.(Stellmann et al., 2014).
AQ5
AQ6
AQ7
2.3. Neuropsychological assessment
Sixteen neuropsychological tests of approximately one hour examined memory,
working memory, attention, and executive functioning: “Verbal Learning and
Memory Test” (VLMT, verbal episodic memory), “repeating numbers” (ZN,
numeric verbal memory), “Test Battery of Attention” (TAP, attention), oral
“Symbol Digit Modality Test” (SDMT, information processing), “Regensburg
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Verbal Fluency Test” (RWT, semantic and phonematic verbal fluency), and
executive functions with the “Performing Assessment System” (LPS) with
subtests for logical reasoning and spatial perception. Results were adjusted for
gender, age, and education. Z-scores were calculated and we computed for each
patient also a mean z-scores over all tests as a global estimate of cognitive
function. We displayed our data in different groups, representing different cutoff
scores (<−2SD, <−1SD, <−1.65SD) in a specific proportion of tests (10%, 20%,
30%, 50% of the tests). However, our main definition classified patients as
cognitive impaired if they scored 1.65 SD below the average (Rao, Leo,
Bernardin, & Unverzagt, 1991) of a normal population in at least 20% of the
tests (for references for neuropsychological assessments and questionnaires see
Table S1).
2.4. Questionnaires
Nine questionnaires with a total of 195 items were applied. These comprised
fatigue (fatigue scale for motor and cognitive functions, FSMC), depression
(quick inventory of depressive symptomatology, QIDS-SR16), cognition
(multiple sclerosis neuropsychological questionnaire, MSNQ), QOL (Hamburg
quality of live instruments in multiple sclerosis, HAQUAMS) activities of daily
living (Frenchay activity index, FAI), leisure time activities (Godin Leisure time
questionnaire, GLTQ), and demographic data. We asked for coping strategies
using the short form questionnaire of the Coping and Self-Efficacy Scale
(CSES) which rates the extent of “one's confidence in performing coping
behaviors when faced with life challenges”. Furthermore, the Sense of
Coherence Scale was applied (SOC 29).
The “Sense of Coherence Scale of Antonovsky” (SOC) is based on the model of
salutogensis, which centers the question what leads to health despite of what
leads to illness. The Sense of Coherence is a “global orientation that expresses
the extent to which one has a pervasive, enduring though, dynamic feeling of
confidence that (a) the stimuli deriving from one's internal and external
environments in the course of living are structured, predictable, and explicable;
(b) the resources are available to one to meet the demands posed by the stimuli,
and (c) these demands are challenges, worthy of investment and engagement”.
Antonovsky called these three components comprehensibility, manageability,
and meaningfulness and represented them in his scale as subcategories
(Antonovxy, 1993). Finally, we asked patients to rate their disease as rather
benign, neutral, or rather malignant.
2.5. Ethics
The Ethics Committee of the Hamburg Chamber of Physicians, Germany
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approved this study (Registration Number: PV4405).
2.6. Statistical analysis
For statistical analysis we used SPSS 19 (spss.com) and R (r-project.org).
Depending on the nature of the data we report descriptive statistics as mean/sd,
median/range, or frequencies. We applied t test and respectively a Person chi-
square test to compare study and dropout patients. To analyze the association
between outcomes, we used linear models or Fisher's exact test. We extracted
R-squared from significant models to quantify the strength of associations. For
plotting, missing R-squared values from significant Fisher's exact tests were set
arbitrarily to a fixed low value of 0.2. All p-values were corrected for multiple
testing with the false discovery rate and were considered significant if still
below 0.05. We analyzed the impact of different outcomes on QOL, the ability
to work and the patient rated severity of their disease in multivariate models
that underwent a stepwise selection of variables based on the Akaike
Information Criterion (Akaike, 2011).
3. RESULTS
3.1. Cohort
Out of 2,904 patients from the database, 879 (30%) had at least 15 years of
disease duration while 234 patients (8.1%) fulfilled also the inclusion criteria
for possibly BMS with an EDSS ≤3.5. Mean EDSS was 2.5 ± 0.9 with a disease
duration of 23.4 ± 6.2 years (mean, SD). One hundred and twenty-five patients
(53% of 234) could be contacted and built the actually studied cohort. Seventy-
nine patients performed clinical assessment including neuropsychological
examination, 10 patients were interviewed by phone and five patients just filled
in questionnaires (for see study flow-chart; Figure 1). Thirty-one patients just
replied with a short feedback letter leading to n = 125 with basic MS
demographic data. There were no significant differences between the cohort and
the dropouts based on the most recent EDSS score (p = 0.58), disease duration
(p = 0.08), age (p = 0.07), and gender (p = 0.42). Only the time since the last
EDSS examination was on average 1.2 years (p < 0.01) shorter in the available
cohort.
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Fig. 1
Composition of the cohort. n = 879 MS database with EDSS <4, Cohort n = 125,
dropouts = 2,779
3.2. Demography
Included patients were on average 51 years old and had a female: male ratio of
3:1. Most patients (65%) had relapsing-remitting MS (RRMS) and had never
(42%), or less than five years (37%) been treated with immunotherapy. Twenty-
one per cent had been treated for more than five years including 2% with
escalation therapies. At the time of assessment 37% patients were on
immunotherapies. Mean EDSS was 2.8 (SD 0.99) including 15% patients with
an EDSS >3.5. From all EDSS Scores (n = 106, Median 2.5 (Range 0–6)), 79
patients were examined due to the study (Median 2.5; Range 0–6) and further
nine patients in the MS-day clinic during the study time (Median 2.5 (1–3.5). In
addition, nine patients were scored by telephone-EDSS (Median 3.0 (2–4).
Nine patients stated to feel stable and we used their last EDSS (Median 2.4,
Range 1–3.5). The most affected functional systems were the pyramidal (mean
1.3, SD 1.1), the sensory (mean 1.39, SD 0.94), and the cerebral (mean 1.14, SD
0.93) system (n = 92). Thirty-nine per cent of patients had an unlimited walking
distance. Assuming the same EDSS distribution in dropouts, the estimated rate
of BMS defined by EDSS ≤3.5 based on all patients with disease
durations>15 years (n = 879) from our database was 22% (199 out of 879;
95%CI: 19.8%–25.4%). The mean 6MWT distance was 466 meters and patients
needed five seconds for the 25FWT and 12 s for the TTW.
The majority had more than 10 years of education (59%), lived in a partnership
(75%), and had children (59%). Thirty-three per cent were working fulltime,
while 20% were retired due to illness. All results are summarized in Table 1, for
further details see Table S2.
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Table 1 Demography
 n (%) n
Sex (f:m) 93:32 (74%: 26%) 125
Age, mean (SD) 51.11 (8.87) 125
Disease duration , mean years (SD) 24.04 (6.89) 125
Disease courses
RRMS 60 (65%)
94
SPMS 23 (25%)
PPMS 5 (5%)
Unknown 5 (5%)
Medication
Never 39 (42%)
94<5 years 32 (37%)
>5 years 20 (21%)
Walking distance
Unlimited 36 (39%)
94
>1,000 29 (32%)
500–1000 m 23 (25%)
300m 4 (4%)
Prestudy EDSS score, mean (SD) 2.5 (0.87) 125
Last EDSS examination
Mean (SD) years ago 2.7 (1.75) 125
Actual EDSS
Total score, mean (SD) 2.8 (0.99)
106
Median (range) 2.5 (0−6)
EDSS ≤2.0 36 (29%)
EDSS 2.5−3.5 69 (56%)
a
d
b
c
e
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EDSS >3.5 19 (15%)
Motor function
9HPT right, mean seconds (SD) 20.21 (0.43)
79
9HPT left mean seconds (SD) 21.66 (0.57)
25FWT, mean seconds (SD) 5.22 (1.52)
TTW mean seconds (SD) 11.52 (5.68)
6MWT mean meter (SD) 465.81 (122.91)
6MWT: 6-min Walking Test; 9HPT: nine-hole peg test; 25FWT: 25-Foot Walk; EDSS: expanded disability scale;
TTW: Timed Tandem Walk.
If not other indicated n (%).
Secondary progressive MS.
Primary progressive MS.
Since first symptoms.
n = 106 (median = 2.7; range 0–6) = study-EDSS n = 79 (median 2.5; range 0–6) + n = 27 (median 3; range 1–4).
3.3. Neuropsychological assessment
In general, the z-scores of memory, working memory, attention, and executive
function tests were within the normal range. Most cognitive deficits were found
in the domains of attention (5%–18%), short term (9%), and working memory
(8%) as well as word fluency (6%–10%).
In summary, 8% of the patients scored 1.65 SD below average in more than 20%
of the cognitive tests and were categorized as cognitively impaired. Using a
cutoff score <−2 SD in more than 10% of the tests 14% of the patients were
affected. Twenty-eight per cent of the patients scored <−1 SD in more than 30%
of the cognitive tests (Table 2). Sixteen patients with an EDSS below 4 were
cognitively impaired resulting in 59.5% of BMS cases if BMS was defined by
EDSS and cognition. Concerning the whole dataset, the corresponding rate of
BMS corrected for cognitive impairment was 15.8% (139 out of 879, 95%; CI:
13.4%–18.2%).
Table 2 Neuropsychological outcome
Meaning Test name Mean
(SD) Affected
SD
Severely
affected
Moderately
affected
Not
affected
a
b
c
d
e
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<−1.65,
% SD <−2,%
SD <−1
and ≥−2,
%
SD
≥−1, %
Memory
Memory
span
VLMTS1 0.24(1.04) 3 0 8 92
ZNfw 0.45(1.23) 3 3 5 92
Learning VLMTS1-5 0.28(0.92) 4 1 6 93
Short Term
Memory VLMT5-7 −0.29(0.95) 9 5 13 82
Recognition VLMTW-F −0.10(0.93) 5 4 11 85
Working
memory
SDMT 0.14(1.02) 8 1 10 89
ZNbw 0.04(1.07) 4 4 20 76
Attention
Alertness
Tonic −0.83(0.77) 11 3 34 63
Phasic −0.89(0.79) 9 2 46 52
Selective
attention GoNoGo
−0.39
(0.93) 5 4 18 78
Divided
attention
Visual −0.25(1.1) 11 8 15 77
Acoustic −0.7(0.99) 18 11 24 65
Executive function
Verbal word
fluency
Semantic 0.69(1.4) 6 4 4 92
Phonematic −0.09(1.23) 10 6 24 70
Logical
reasoning LPS3
0.74
(0.50) 0 0 0 100
a
b
05/03/2019, 13*27e.Proofing
Page 11 of 22https://wileyproofs.sps.co.in/eproofing_wiley_v2/printpage.php?token=KpVRj3PKFbEzdoTKCZH6e9vgOwQD1r3X
Spatial
perception LPS7
0.60
(0.70) 0 0 1 99
Score
More than
50% tests
abnormal
  0 0 2.5  
More than
30% tests
abnormal
  5 1 28  
More than
20% tests
abnormal
  8 3 35  
More than
10% tests
abnormal
  25 14 60  
n = 79.
VLMT: “Verbal Learning and Memory Test”; ZN: repeating numbers Test; SDMT: “Symbol Digit Modality Test”;
RWT: Regensburg Verbal Fluency Test; LPS: Performing Assessment System.
Forward
Backward.
3.4. Questionnaires
Results from the questionnaires are summarized in Table 3. Based on MSNQ,
27% of the patients rated themselves as cognitively affected. Mean QIDS score
of 6.31 (SD 4.53) indicated mild depressive symptomatology. One-third of the
patients had low grade depressive symptoms, 9% moderate, and 7% severe
depression. Seventy-three per cent showed pathological FSMC total scores
including 43% patients with severe fatigue. The three reported main symptoms
in the HAQUAMS were walking difficulties (33%), fatigue (20%), and sensory
symptoms (15%). Asked for their overall QOL patients mean score on a single
fife point Likert scale item was 3.51 which means “quite satisfied”. The CSES
total score (possible range 0–10 with higher values indicating higher coping
abilities) showed a mean of 6.38 (SD 2.19) with the social support subcategory
scoring highest. The SOC mean score of 5.1 (SD 0.84) was similar to healthy
population data (Schumacher, Wilz, Gunzelmann, & Brähler, 2000). The main
activities which patients did not perform at all according to the FAI were
“gardening” (40%), “travel outing/car ride” (21%), and “heavy household
work” (13%) (Table S3). The GLTQ indicated that the cohort did in average
0.66 times per week light, 1.74 times per week moderate, and 1.75 times per
week strenuous exercise. Seventy-five (76%) patients estimated their MS form
a
b
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as benign, six (8%) as malignant, and 12 (16%) as neutral.
Table 3 Patient reported outcome measures (n = 94)
 Mean (SD) Mean/question (SD)
MSNQ
Total score 18.52 (9.25) 1.23 (0.62)
QIDS16
Total score 6.31 (4.53) 0.70 (0.50)
FSMC
Total score 57.43 (21.5) 2.87 (1.07)
Cognitive fatigue 27.34 (11.25) 2.73 (1.13)
Motor fatigue 30.1 (11.07) 3.01 (1.12)
CSES
Total score 82.87 (28.58) 6.38 (2.19)
Problem focused 39.32 (13.96) 6.55 (2.33)
Emotion focused 22.21 (11.06) 5.55 (2.77)
With social support 21.34 (6.94) 7.12 (2.31)
SOC
Total score 146.8 (24.45) 5.1 (0.84)
HAQUAMS
Total score  2.06 (0.64)
Fatigue  2.29 (1.11)
Cognition  2.30 (1.08)
Lower extremity  2.21 (0.86)
Upper extremity  1.46 (0.60)
Communication  1.97 (0.88)
FAI
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Total score 31.19 (6.68) 2.08 (0.45)
GLTQ
Score 19.55 (20.55)  
Note
CSES: Coping and Self-Efficacy Scale; FAI: Frenchay activity index; FSMC: fatigue scale for motor and cognitive
functions; GLTQ: Godin Leisure time questionnaire; HQUAMS: Hamburg quality of live instruments in multiple
sclerosis; MSNQ: multiple sclerosis neuropsychological questionnaire; QIDS-16: quick inventory of depressive
symptomatology; SOC: Sense of Coherence Scale.
3.5. Associations
The association and dependencies between outcomes are summarized in Figure
2. We observed approximately four clusters: EDSS/mobility (TTW, T25FW,
6MWT, 9HPT), neuropsychology, family status, and PROMS. However, there
were only few links between the clusters (Figure S1). QOL assessed with the
HAQUAMS had a prominent position within the network of associations
bridging between disability measures as EDSS or fatigue and family status,
coping, and mood. Interestingly, cognitive impairment (summarized as mean-z
score) and immunotherapies were rather independent from other outcomes.
Furthermore, there was no difference concerning EDSS, SDMT, and Fatigue
between patients with and without actual immunotherapies. Age and disease
duration were not related to any other measurement.
a
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Fig. 2
Correlations between outcomes. Red color stands for negative correlation, blue
for positive correlations. The thickness of the lines pictures the strengths of the
correlation. Just significant correlations after correction for multiple testing are
shown. CI: cognitive impairment; cogMean: computed mean z-score of all
neuropsychological tests; 9HPT: Nine-Hole Peg Test; CSES: Coping Self-
Efficacy Scale; SOC: Sense of Coherence; IDS: Quick Inventory of Depressive
Symptomatology, QIDS-SR16; MSNQ: Multiple Sclerosis Neuropsychological
Questionnaire; HAQUAMS: Hamburg Quality of Live Scale in Multiple
Sclerosis; FSMC: Fatigue Scale for Motor and Cognitive Functions; EDSS:
Expanded Disability Status Scale; TTW: Timed Tandem Walk; T75: 25-Foot
Walk; Godin: Godin leisure time activities
3.6. Multivariate models
To elucidate, what determines QOL, we investigated the impact of disease
duration, coping, EDSS, cognition, fatigue, medication, ability to work, and
depression. After stepwise selection of variables, the HAQUAMS score was
substantially explained (R =0.68) by EDSS (p = 0.001), FSMC (p < 0.001), IDS2
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(p < 0.001), and occupational situation (p = 0.038). In this context, we analyzed
also the difference in QOL comparing differently defined BMS groups and
observed a significant better QOL in BMS patients defined by EDSS alone
(p = 0.014) while BMS groups defined by cognitive impairment and EDSS did
not differ in QOL (p = 0.15). The ability to work was weakly explained by the
HAQUAMS score alone (R  = 0.11, p = 0.010), while disease duration, coping,
EDSS, 6MWT, NHPT, cognition, depression, or fatigue did not contribute.
Patients rating of severity of their MS depended (p = 0.007) on coping and
cognition. Lower coping scores were associated with a rating of MS as a severe
condition. QOL, disease duration, EDSS, 6MWT, 9HPT, Fatigue, medication,
and depression did not contribute to the rating. Patients with a cognitive
impairment avoided to rate their disease as benign or malignant and favored the
neutral response. See Figure 2 (Figure S1).
4. DISCUSSION
Studying a cohort of presumably benign MS we found restrictions in motor
function, fatigue, and depression but with only moderate influence on patients
QOL. Cognitive deficits showed a striking low prevalence. Seventy-five per
cent of the patients rated their MS themselves as benign. Depending on the
inclusion of cognitive impairment in the BMS definition, the rate of BMS in our
dataset of long standing MS (n = 879) ranged between 16% and 23%.
Interestingly, although having applied a MS sensitive neuropsychological
battery only 8% of patients had a substantial cognitive deficit. The few studies
addressing cognitive impairment in BMS show a large variance from 17% to
47% (Amato et al., 2006; Correale, Ysrraelit, & Fiol, 2012; Cristina et al., 2017;
Gajofatto, Turatti, Bianchi, & Forlivesi, 2015). Cognitive impairment that is
common in MS, seems to be independent from other disability dimensions and
might indicate a higher risk for later disability progression (Correale, Ysrraelit
et al., 2012; Cristina et al., 2017; Portaccio et al., 2009; Rao et al., 1991; Sayao,
Devonshire, & Tremlett, 2007). However, different neuropsychological batteries
and cutoff scores to define cognitive impairment restricts comparability of
studies (Cristina et al., 2017; Fischer et al., 2014). While most studies define
two-three tests scores below −2 SD of a normal population as cognitive
impairment, the ecologic validity of such a definition for impairment in daily
life remains a matter of discussion (Gajofatto et al., 2015). Here, we observed
also no relevant association between cognitive performance and QOL or FAI.
In contrast, 73% of our patients indicated a substantial amount of fatigue that is
above other BMS studies reporting 33% to 54% of affected patients (Amato et
al., 2006; Correale, Peirano et al., 2012; Sayao et al., 2011). Fatigue scores were
2
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closely associated with depression and coping and thus contributing to QOL.
However, HAQUAMS mean scores were still 0.15-0.42 points lower than in
other MS cohorts meaning a better QOL. Given a minimal important difference
of 0.2 points, our results indicate a preserved high QOL in our cohort (Gold et
al., 2010; Schäffler et al., 2013). Thus, even a high prevalence of high FSMC
fatigue scores did not severely impact on the QOL of our patients. Similar, daily
activities as assessed by FAI showed high functionality above for example a
population based MS cohort in Stockholm (Einarsson, Gottberg, Fredrikson,
von Koch, & Holmqvist, 2006). Still 20% of our cohort stated to be retired due
to MS. Sayao et al. also found a higher QOL and higher employment rates in
long-term BMS patients than in those not staying benign (Sayao et al., 2011).
In our cohort, we identified QOL as an exclusive but very weak predictor for
employment status.
Overall, QOL showed strong associations with a broad range of health
dimensions. As contributing factor for a high QOL, we found a supporting
background, effective coping strategies as well as a good sense of coherence.
Especially, the patients’ impression of a benign disease was associated with
better coping abilities. Most patients reported a high level of coping self-
efficacy. Social support was the strongest contributive factor. In addition, most
of our patients lived in a partnership and had children which is in contrast to
previous observations in the general MS population reporting higher divorce
rates (Pfleger, Flachs, & Koch-henriksen, 2010) and lower pregnancy rates.
(Alwan, Chambers, Armenti, & Sadovnick, 2015) Our findings indicate a high
level of social integration and support in our sample. In addition, Sense of
Coherence (SOC) scores were overall high and (Eriksson & Lindström, 2005)
only 8% of our patients scored 1.65 SD below the average scores from a
population-based study in healthy German people (n = 2005) (Schumacher et
al., 2000). Thus, our MS patients resembled healthy individuals in their
perception of meaningfulness of life.
At the time of the actual examination about 15% of the patients showed EDSS
scores ≥3.5 and only 39% reported an unlimited walking range.
Correspondingly, other motor-focused objective assessments as the TTW
(Stellmann et al., 2014) and the 6MWT (Goldman et al., 2008) showed
impairment. Among all objective outcomes, mobility restrictions contributed
highest to the QOL underlining previous reports about the importance of
walking abilities for MS patients (Heesen et al., 2017). In contrast, having had
immunotherapies did not seem to influence any of our outcomes including
QOL.
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In our cohort, 30% of patients had some sort of progressive disease course.
While a consensus group defined BMS independently of the disease course
phenotype (Lublin et al., 2014), Skoog et al. proposed the absence of
progression as a condition to define BMS (Skoog, Tedeholm, Runmarker, Odén,
& Andersen, 2014). However, even primary-progressive MS patients presumed
to have a worse prognosis show a heterogeneous disease evolution. Therefore,
we decided against a paradigmatic exclusion of a possibly benign progressive
disease course (Stellmann, Neuhaus, Lederer, Daumer, & Heesen, 2014). Here,
we observed only a moderate association between the disease course and
disability while QOL or FAI were independent from the disease course.
As a limitation nearly half of the patients could not be contacted and only a
third could be assessed clinically. But baseline demographic data of these
compared to the analyzed cohort gave no indication of a selection bias. In
addition, we hypothesized that especially minor impaired MS patients might not
seek medical attention at a tertiary referral clinic. Thus, a negative selection
bias might rather lead to an overestimation of impairment in the clinically
investigated cohort. Even though the EDSS of the majority of patients were
clinically assessed, we used also in some cases retrospective data which is a
further limitation. Furthermore, this study included no healthy control cohort
but referred to normative data from the literature which weakens the validity of
findings to some extent.
In conclusion, existence and prevalence of BMS is a heavily disputed scientific
topic (Amato & Portaccio, 2012; Cristina et al., 2017; Lublin, 2014) and our
data add to the complexity of the picture. Presumably benign patients seem to
have some impairment as especially walking restriction and fatigue but most
patients live their lives as they want to. Seventy-five per cent of the patients
rated their MS as benign reflected in high SOC and QOL scores.
Thus we propose that BMS needs to be defined at least partially by educated
patients themselves based on their estimates how far MS impacts their life goals
and impairs their ability to adapt to life challenges. This view might help to
stress rather resources and resilience than clinical deficits. Highly sensitive
disability measures as for example neuropsychological batteries have a
questionable value for a given patient and might not be the best approach to
define “benign” in a patient centered way.
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